This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Feb. 16, 2012

   Home   Mission/Vision    Membership    Corporate Membership    CME/CEU    JMCM    Contact Us

Click Here to view the Journal of Managed Care Medicine

Online CME/CEU Programs
Multiple Myeloma: An Update on Diagnostic and Treatment Strategies

Advanced Treatment of Osteoporosis in Postmenopausal Women

Decreasing the Cost Burden of Fibromyalgia with Early Diagnosis and Management

 



 Genomics


New prenatal genetic test is more powerful
UPI    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Testing a developing fetus' DNA via chromosomal microarray gives more information about disorders than standard prenatal testing, U.S. researchers say. The researchers, led by Dr. Ronald Wapner, director of reproductive genetics at NewYork-Presbyterian Hospital/Columbia University Medical Center and of Columbia University College of Physicians and Surgeons, found that in women having routine prenatal diagnosis, chromosomal microarray detected additional genetic abnormalities in about 1 in 70 fetal samples that had a normal karyotype. More



Newly identified fusion genes in lung and colorectal cancer may guide treatment with 'targeted' drugs
HealthCanal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Novel gene abnormalities discovered in a subpopulation of lung and colorectal tumors could potentially identify patients with a good chance of responding to highly specific "targeted" drugs already in use for treating other cancers, scientists report. The genetic alterations — pieces of two genes fused together — showed up in a massive search of the DNA in stored tumor samples of non-small cell lung cancer and colorectal cancer, said researchers from Dana-Farber Cancer Institute and Foundation Medicine, Inc. More

Why a DNA test may not save your life
The Globe and Mail    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Imagine opening your mailbox to discover how likely it is you'll have a heart attack or whether you have a predisposition to Alzheimer's disease or cancer. Thanks to advances in direct-to-consumer genetic testing, this scenario is moving from the realm of science fiction to reality. More

 Biotech/Diagnostics/Personalized Medicine


FDA approves Gen-Probe's prostate cancer diagnostic test
Proactive Investors    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Gen-Probe said U.S. health regulators approved its diagnostic test Progensa PAC3 which is used to verify the need for repeat biopsies in men at risk of getting prostate cancer. The company makes molecular diagnostic products and services to diagnose diseases and screen donated blood. Gen-Probe acquired worldwide diagnostics rights to the biomarker Prostate Cancer Antigen 3 gene from DiagnoCure in 2003. More

Study: Satisfied patients not always healthiest
The Sacramento Bee    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The most satisfied patients may not be the healthiest ones. In fact, satisfied patients are more likely to be hospitalized, have higher healthcare costs and be more likely to die than less-satisfied ones, according to a study released by UC Davis researchers More

Gauging hype during Heart Month: 5 tests you might not need
HealthNews    Share    Share on FacebookTwitterShare on LinkedinE-mail article
February is American Heart Month and consumers will be bombarded with advice to keep their tickers healthy — whether it's from the American Heart Association's Go Red For Women or the National Heart, Lung, and Blood Institute's The Heart Truth. Doctors may suggest a screening test to make sure cardiovascular health is in top shape. But if a person lacks symptoms — like chest pain or shortness of breath — they might want to hit pause for a second and look closer at the costs and benefits. More


Introducing mySentry™ from Medtronic...

The world’s first remote glucose monitor designed to provide protection from overnight hypoglycemia. MORE
Our activities touch many lives
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for cancer, cardiovascular, gastrointestinal and infection. MORE


 Regenerative Medicine


Radiation treatment transforms breast cancer cells into cancer stem cells
Medical Xpress    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Now, researchers with the UCLA Department of Radiation Oncology at UCLA's Jonsson Comprehensive Cancer Center report for the first time that radiation treatment — despite killing half of all tumor cells during every treatment — transforms other cancer cells into treatment-resistant breast cancer stem cells. The generation of these breast cancer stem cells counteracts the otherwise highly efficient radiation treatment. More

Stem cell stocks: Mending scarred hearts
The Motley Fool via DailyFinance    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A new study at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. This is certainly exciting news considering heart failure is still the No. 1 cause of death in men and women. The study included 25 heart attack victims, 17 of whom got the stem cell treatment. Those patients saw a 50 percent reduction in cardiac scar tissue after one year, while the eight control patients saw no improvement. More

 Emerging Medical Technologies


Emerging medical technology is cool — but is it useful?
FierceHealthIT    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Medical technology is cool, but "there's a huge gap between the way many technologists envision medical problems and the way problems are actually experienced by physicians and patients," says David Shaywitz, writing for Forbes about the recent FutureMed event in Silicon Valley. Even informal discussions at the event revolved around big questions, lofty ideas, and the next big thing, from artificial organs created from stem cells to computers that can read minds, and bottom-up innovation, he writes. More

Medical innovation: How the US can retain its lead
The Wall Street Journal    Share    Share on FacebookTwitterShare on LinkedinE-mail article
We stand on the cusp of a revolution in healthcare. Advances in molecular medicine will allow us to develop powerful new treatments that can cure or even prevent diseases like Alzheimer's and cancer. Tomorrow's high-tech cures can also slash healthcare costs and eliminate ineffective treatments. What will it take to realize the potential of the new medicine? More

 Managed Healthcare News


Feds beef up screening for Medicare providers; agency recovered $4.1 billion last year
The Associated Press via The Washington Post    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Federal authorities say they recovered $4.1 billion in healthcare fraud judgments last year, a record high which officials credited to new tools for cracking down on deceitful Medicare claims. The recovered funds are up roughly 50 percent from 2009. Attorney General Eric Holder and Department of Health and Human Services Secretary Kathleen Sebelius were expected to make the announcement at a news conference. More

Young adults on parents' health insurance have more access to care
WebMD    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Allowing children to stay on their parents' health insurance past the age of 18 increased young adults' chances of having a physical exam and made them less likely to go without care due to cost, according to a new study. To understand how the new Affordable Care Act may influence young adults' use of health services, researchers compared health data from states that had laws enacted in 2005 or 2006, allowing young people to join their parents' policies, to states without them. More

 FDA: New Treatments and Technology


FDA outlines path for lower-priced biotech drugs
The Associated Press via USA Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The Food and Drug Administration is preparing to review the first lower-cost versions of biotech drugs, expensive medications which have never before faced generic competition. The guidelines issued by the FDA are the final step in a decades-long effort to lower the price of biotech drugs, high-tech injectable medications that cost the nation billions of dollars each year. More

FDA warning: Counterfeit version of cancer drug Avastin circulating
Drug Topics    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Some cancer patients may not get proper treatment because a counterfeit version of the drug sold as Avastin has been purchased by as many as 19 medical practices in the United States, FDA warned. Avastin is used to treat certain types of cancer, including lung cancer and cancer of the colon or rectum that has spread to other parts of the body. The counterfeit drug does not contain the medication's active ingredient, bevacizumab, FDA said. More

FAST FACTS
"A chemical in the NeurogesX patch under FDA review is capsaicin, found in chili peppers. According to the Mayo Clinic, capsaicin is used to relieve arthritis and muscle sprains."
 
Genomics Biotech and Emerging Medical Technologies Institute eBrief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Christine Kraly, Content Editor, 469.420.2685   
Contribute news

This edition of the Genomics Biotech and Emerging Medical Technologies Institute eBrief was sent to %%emailaddr%%. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
Feb. 9, 2012
Feb. 2, 2012
Jan. 26, 2012
Jan. 19, 2012



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063